PMID- 33816057
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 2196-3029 (Print)
IS  - 2196-3029 (Electronic)
VI  - 7
IP  - 3
DP  - 2020 Sep
TI  - CAR-Tregs as a Strategy for Inducing Graft Tolerance.
PG  - 205-214
LID - 10.1007/s40472-020-00285-z [doi]
AB  - PURPOSE OF THE REVIEW: The adoptive transfer of alloantigen-specific regulatory T 
      cells (Tregs) following organ transplantation is an emerging treatment paradigm 
      that may induce tolerance and reduce the risk for graft rejection. In particular, 
      redirecting Treg specificity via expression of synthetic chimeric antigen 
      receptors (CARs) has demonstrated therapeutic promise in several preclinical 
      studies. In this review, we highlight recent progress and remaining barriers to 
      the clinical translation of CAR-Treg therapies. RECENT FINDINGS: CAR Tregs 
      targeting human leukocyte antigen (HLA)-A2 showed antigen-specific in vitro 
      activation and superior in vivo protective function relative to polyclonal Tregs. 
      Adoptively transferred anti-HLA-A2 CAR Tregs prolonged the survival of 
      HLA-A2-positive grafts in humanized mouse models. SUMMARY: Donor HLA molecules 
      are attractive candidate antigens to target with CAR Tregs in transplantation due 
      to mismatched HLA only expressed on the transplanted organ. The feasibility of 
      this approach has been demonstrated by several independent groups in recent 
      years. However, substantial challenges in CAR design and preclinical modeling 
      must be more extensively addressed prior to clinical application.
FAU - Wagner, Johanna C
AU  - Wagner JC
AD  - Division of Transplantation, Department of Surgery, University of California San 
      Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA.
AD  - University Hospital Wurzburg, Department of General, Visceral, Transplantation, 
      Vascular and Pediatric Surgery, Oberdurrbacherstr. 6, 97080 Wurzburg, Germany.
FAU - Tang, Qizhi
AU  - Tang Q
AD  - Division of Transplantation, Department of Surgery, University of California San 
      Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA.
AD  - UCSF Diabetes Center, University of California San Francisco, 513 Parnassus Ave, 
      San Francisco, CA 94143, USA.
LA  - eng
GR  - U01 AI110658/AI/NIAID NIH HHS/United States
GR  - UC4 DK116264/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20200704
PL  - Switzerland
TA  - Curr Transplant Rep
JT  - Current transplantation reports
JID - 101624626
PMC - PMC8011668
MID - NIHMS1609308
OTO - NOTNLM
OT  - CAR
OT  - HLA
OT  - Tregs
OT  - tolerance
OT  - transplantation
EDAT- 2021/04/06 06:00
MHDA- 2021/04/06 06:01
PMCR- 2021/09/01
CRDT- 2021/04/05 06:06
PHST- 2021/04/05 06:06 [entrez]
PHST- 2021/04/06 06:00 [pubmed]
PHST- 2021/04/06 06:01 [medline]
PHST- 2021/09/01 00:00 [pmc-release]
AID - 10.1007/s40472-020-00285-z [doi]
PST - ppublish
SO  - Curr Transplant Rep. 2020 Sep;7(3):205-214. doi: 10.1007/s40472-020-00285-z. Epub 
      2020 Jul 4.